Process for the manufacture of (2S,3S,4S,5R,6S)-3,4,5-trihydroxy-6-(((4AR,10AR)-7-hydroxy-1-propyl-1,2,3,4,4A,5,10,10A-octahydrobenzo[g]quinolin-6-yl)oxy)tetrahydro-2H-pyran-2-carboxylic acid

1. A process for the preparation of compound (Id)

or a pharmaceutically acceptable salt thereof,

comprising deprotecting compound (A3) to obtain compound (Id), or a pharmaceutically acceptable salt thereof, according to the reaction scheme below:

2. The process of claim 1 , comprising deprotecting compound (A3) by contacting compound (A3) with a nucleophilic reagent to obtain compound (Id), or a pharmaceutically acceptable salt thereof.

3. The process according to claim 2 , further comprising the step of isolating compound (Id), or a pharmaceutically acceptable salt thereof.

4. The process according to claim 2 , wherein said nucleophilic reagent is selected from potassium hydroxide, potassium cyanide, and sodium hydroxide.

5. The process according to claim 2 , wherein said deprotection takes place in a mixture of methanol and water.

6. The process according to claim 2 , wherein compound (Id) is obtained as a potassium salt of compound (Id), and wherein potassium hydroxide or potassium cyanide is used as nucleophilic reagent.

7. The process according to claim 2 , wherein compound (Id) is obtained as a potassium salt of compound (Id), and wherein potassium hydroxide is used as nucleophilic reagent.

8. The process according to claim 2 , wherein compound (Id) is obtained as a sodium salt of compound (Id), and wherein sodium hydroxide is used as nucleophilic reagent.

9. The process according to claim 4 , wherein compound (Id) is obtained in a solution, and the process further comprises neutralizing the solution with a strong acid.

10. The process according to claim 9 , wherein the strong acid is HCl.

11. The process according to claim 2 , wherein compound (Id) is obtained as (2S,3S,4S,5R,6S)-3,4,5-trihydroxy-6-(((4aR,10aR)-7-hydroxy-1-propyl-1,2,3,4,4a,5,10,10a-octahydrobenzo[g]quinolin-6-yl)oxy)tetrahydro-2H-pyran-2-carboxylic acid heptahydrate.

12. The process according to claim 6 , further comprising formulating the potassium salt of compound (Id) into a solid oral dosage form.

13. The process according to claim 7 , further comprising formulating the potassium salt of compound (Id) into a solid oral dosage form.

14. The process according to claim 8 , further comprising formulating the sodium salt of compound (Id) into a solid oral dosage form.

15. The process according to claim 9 , further comprising formulating compound (Id), or a pharmaceutically acceptable salt thereof, into a solid oral dosage form.

16. The process according to claim 11 , further comprising formulating (2S,3S,4S,5R,6S)-3,4,5-trihydroxy-6-(((4aR,10aR)-7-hydroxy-1-propyl-1,2,3,4,4a,5,10,10a-octahydrobenzo[g]quinolin-6-yl)oxy)tetrahydro-2H-pyran-2-carboxylic acid heptahydrate compound (Id) into a solid oral dosage form.

17. The process according to claim 2 , wherein compound (A3) is prepared using the following step

reacting compound (A2) with (2S,3S,4S,5R,6R)-2-(methoxycarbonyl)-6-(2,2,2-trichloro-1-iminoethoxy)tetrahydro-2H-pyran-3,4,5-triyl triacetate to obtain compound (A3) according to the reaction scheme below

wherein said reaction takes place in an aprotic solvent in the presence of a Lewis acid.

18. The process according to claim 17 , further comprising the step of isolating compound (A3).

19. The process according to claim 17 , wherein said aprotic solvent is dichloromethane or benzotrifluoride.

20. Previously presented 17 , The process according to claim 17 , wherein said aprotic solvent is dichloromethane, and said Lewis acid is boron trifluoride diethyl etherate.

21. The process according to claim 17 , wherein said aprotic solvent is benzotrifluoride, and said Lewis acid is boron trifluoride diethyl etherate.